Merck made $3B-plus offer for MoonLake—and could revive interest in late-phase biotech: FT
Barreling toward the loss of exclusivity on Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease prospect to its late-phase pipeline.
Barreling toward the loss of exclusivity on Keytruda, Merck & Co. has reportedly offered $3 billion to buy MoonLake Immunotherapeutics to add an inflammatory disease prospect to its late-phase pipeline.
